Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice

ACS Infectious Diseases

Volumn 2, Issue 4, 2016, Pages 251-267

  Irwin, Scott M ^a   Prideaux, Brendan ^b   Lyon, Edward R ^a   Zimmerman, Matthew D ^b   Brooks, Elizabeth J ^a   Schrupp, Christopher A ^a   Chen, Chao ^b   Reichlen, Matthew J ^c   Asay, Bryce C ^a   Voskuil, Martin I ^c   Nuermberger, Eric L ^d   Andries, Koen ^e   Lyons, Michael A ^a   Dartois, Véronique ^b   Lenaerts, Anne J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

bedaquiline; C3HeB FeJ; mouse models; pyrazinamide; tuberculosis

Indexed keywords

BEDAQUILINE; PYRAZINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; C3HEB/FE MOUSE; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG TISSUE LEVEL; FEMALE; LUNG GRANULOMA; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

EID: 85019538613     PISSN: None     EISSN: 23738227     Source Type: Journal    
DOI: 10.1021/acsinfecdis.5b00127     Document Type: Article

References (49)

1. Canetti, G. (1955) The tubercle bacillus in the pulmonary lesion of man; histobacteriology and its bearing on the therapy of pulmonary tuberculosis, American rev. ed., Springer Publishing Co., New York, NY.
2. Hunter, R. L., Actor, J. K., Hwang, S. A., Karev, V., and Jagannath, C. (2014) Pathogenesis of post primary tuberculosis: immunity and hypersensitivity in the development of cavities Ann. Clin. Lab. Sci. 44, 365-387
3. Lenaerts, A., Barry, C. E., 3rd, and Dartois, V. (2015) Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses Immunol Rev. 264, 288-307 10.1111/imr.12252
4. Bumann, D. (2015) Heterogeneous host-pathogen encounters: act locally, think globally Cell Host Microbe 17, 13-19 10.1016/j.chom.2014.12.006
5. Driver, E. R., Ryan, G. J., Hoff, D. R., Irwin, S. M., Basaraba, R. J., Kramnik, I., and Lenaerts, A. J. (2012) Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis Antimicrob. Agents Chemother. 56, 3181-3195 10.1128/AAC.00217-12
6. Irwin, S. M., Driver, E., Lyon, E., Schrupp, C., Ryan, G., Gonzalez-Juarrero, M., Basaraba, R. J., Nuermberger, E. L., and Lenaerts, A. J. (2015) Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with Mycobacterium tuberculosis Dis. Models & Mech. 8, 591-602 10.1242/dmm.019570
7. Irwin, S. M., Gruppo, V., Brooks, E., Gilliland, J., Scherman, M., Reichlen, M. J., Leistikow, R., Kramnik, I., Nuermberger, E. L., Voskuil, M. I., and Lenaerts, A. J. (2014) Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas Antimicrob. Agents Chemother. 58, 4026-4034 10.1128/AAC.02565-14
8. Yano, T., Kassovska-Bratinova, S., Teh, J. S., Winkler, J., Sullivan, K., Isaacs, A., Schechter, N. M., and Rubin, H. (2011) Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species J. Biol. Chem. 286, 10276-10287 10.1074/jbc.M110.200501
9. Lanoix, J. P., Lenaerts, A. J., and Nuermberger, E. L. (2015) Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis Dis. Models & Mech. 8, 603-610 10.1242/dmm.019513
10. Koul, A., Vranckx, L., Dendouga, N., Balemans, W., Van den Wyngaert, I., Vergauwen, K., Gohlmann, H. W., Willebrords, R., Poncelet, A., Guillemont, J., Bald, D., and Andries, K. (2008) Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis J. Biol. Chem. 283, 25273-25280 10.1074/jbc.M803899200
11. Veziris, N., Ibrahim, M., Lounis, N., Andries, K., and Jarlier, V. (2011) Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis PLoS One 6, e17556 10.1371/journal.pone.0017556
12. Williams, K., Minkowski, A., Amoabeng, O., Peloquin, C. A., Taylor, D., Andries, K., Wallis, R. S., Mdluli, K. E., and Nuermberger, E. L. (2012) Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis Antimicrob. Agents Chemother. 56, 3114-3120 10.1128/AAC.00384-12
13. Diacon, A. H., Donald, P. R., Pym, A., Grobusch, M., Patientia, R. F., Mahanyele, R., Bantubani, N., Narasimooloo, R., De Marez, T., van Heeswijk, R., Lounis, N., Meyvisch, P., Andries, K., and McNeeley, D. F. (2012) Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance Antimicrob. Agents Chemother. 56, 3271-3276 10.1128/AAC.06126-11
14. Diacon, A. H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., Venter, A., Allen, J., Palomino, J. C., De Marez, T., van Heeswijk, R. P., Lounis, N., Meyvisch, P., Verbeeck, J., Parys, W., de Beule, K., Andries, K., and Mc Neeley, D. F. (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis N. Engl. J. Med. 360, 2397-2405 10.1056/NEJMoa0808427
15. Anonymous (1981) Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis Lancet 317, 171-174 10.1016/S0140-6736(81)90057-X
16. Combs, D. L., O'Brien, R. J., and Geiter, L. J. (1990) USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results Ann. Intern. Med. 112, 397-406 10.7326/0003-4819-76-3-112-6-397
17. Ahmad, Z., Fraig, M. M., Bisson, G. P., Nuermberger, E. L., Grosset, J. H., and Karakousis, P. C. (2011) Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections Antimicrob. Agents Chemother. 55, 1527-1532 10.1128/AAC.01524-10
18. Ibrahim, M., Andries, K., Lounis, N., Chauffour, A., Truffot-Pernot, C., Jarlier, V., and Veziris, N. (2007) Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis Antimicrob. Agents Chemother. 51, 1011-1015 10.1128/AAC.00898-06
19. Diacon, A. H., Dawson, R., von Groote-Bidlingmaier, F., Symons, G., Venter, A., Donald, P. R., van Niekerk, C., Everitt, D., Winter, H., Becker, P., Mendel, C. M., and Spigelman, M. K. (2012) 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial Lancet 380, 986-993 10.1016/S0140-6736(12)61080-0
20. Zhang, Y., Wade, M. M., Scorpio, A., Zhang, H., and Sun, Z. (2003) Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid J. Antimicrob. Chemother. 52, 790-795 10.1093/jac/dkg446
21. Shi, W., Zhang, X., Jiang, X., Yuan, H., Lee, J. S., Barry, C. E., 3rd, Wang, H., Zhang, W., and Zhang, Y. (2011) Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis Science 333, 1630-1632 10.1126/science.1208813
22. Zhang, S., Chen, J. Z., Shi, W. L., Liu, W., Zhang, W. H., and Zhang, Y. (2013) Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis Emerging Microbes Infect. 2, e34 10.1038/emi.2013.38
23. Tasneen, R., Li, S. Y., Peloquin, C. A., Taylor, D., Williams, K. N., Andries, K., Mdluli, K. E., and Nuermberger, E. L. (2011) Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis Antimicrob. Agents Chemother. 55, 5485-5492 10.1128/AAC.05293-11
24. Global Alliance for Tuberculosis Drug Development. A Phase 2 Open Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. (NC-005), in ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02193776?term=nc-005&rank=1, Bethesda, MD.
25. Zhang, Y., Permar, S., and Sun, Z. (2002) Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide J. Med. Microbiol. 51, 42-49 10.1099/0022-1317-51-1-42
26. Rouan, M. C., Lounis, N., Gevers, T., Dillen, L., Gilissen, R., Raoof, A., and Andries, K. (2012) Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis Antimicrob. Agents Chemother. 56, 1444-1451 10.1128/AAC.00720-11
27. Ahmad, Z., Nuermberger, E. L., Tasneen, R., Pinn, M. L., Williams, K. N., Peloquin, C. A., Grosset, J. H., and Karakousis, P. C. (2010) Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig J. Antimicrob. Chemother. 65, 729-734 10.1093/jac/dkq007
28. Via, L. E., Savic, R., Weiner, D. M., Zimmerman, M. D., Prideaux, B., Irwin, S. M., Lyon, E., O'Brien, P., Gopal, P., Eum, S., Lee, M., Lanoix, J. P., Dutta, N. K., Shim, T., Cho, J. S., Kim, W., Karakousis, P. C., Lenaerts, A., Nuermberger, E., Barry, C. E., 3rd, and Dartois, V. (2015) Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives ACS Infect. Dis. 1, 203-214 10.1021/id500028m
29. Kjellsson, M. C., Via, L. E., Goh, A., Weiner, D., Low, K. M., Kern, S., Pillai, G., Barry, C. E., 3rd, and Dartois, V. (2012) Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions Antimicrob. Agents Chemother. 56, 446-457 10.1128/AAC.05208-11
30. Svensson, E. M., Aweeka, F., Park, J. G., Marzan, F., Dooley, K. E., and Karlsson, M. O. (2013) Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis Antimicrob. Agents Chemother. 57, 2780-2787 10.1128/AAC.00191-13
31. Prideaux, B. and Stoeckli, M. (2012) Mass spectrometry imaging for drug distribution studies J. Proteomics 75, 4999-5013 10.1016/j.jprot.2012.07.028
32. Dartois, V. (2014) The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells Nat. Rev. Microbiol. 12, 159-167 10.1038/nrmicro3200
33. Prideaux, B., Dartois, V., Staab, D., Weiner, D. M., Goh, A., Via, L. E., Barry, C. E., 3rd, and Stoeckli, M. (2011) High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions Anal. Chem. 83, 2112-2118 10.1021/ac1029049
34. Dhillon, J., Andries, K., Phillips, P. P., and Mitchison, D. A. (2010) Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells Tuberculosis (Oxford, U. K.) 90, 301-305 10.1016/j.tube.2010.07.004
35. Baik, J., Stringer, K. A., Mane, G., and Rosania, G. R. (2013) Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response Antimicrob. Agents Chemother. 57, 1218-1230 10.1128/AAC.01731-12
36. Barry, V. C., Belton, J. G., Conalty, M. L., Denneny, J. M., Edward, D. W., O'Sullivan, J. F., Twomey, D., and Winder, F. (1957) A new series of phenazines (rimino-compounds) with high antituberculosis activity Nature 179, 1013-1015 10.1038/1791013a0
37. Prideaux, B., Via, L. E., Zimmerman, M. D., Eum, S., Sarathy, J., O'Brien, P., Chen, C., Kaya, F., Weiner, D. M., Chen, P. Y., Song, T., Lee, M., Shim, T. S., Cho, J. S., Kim, W., Cho, S. N., Olivier, K. N., Barry, C. E., 3rd, and Dartois, V. (2015) The association between sterilizing activity and drug distribution into tuberculosis lesions Nat. Med. 21, 1223-1227 10.1038/nm.3937
38. Zhang, Y. and Mitchison, D. (2003) The curious characteristics of pyrazinamide: a review Int. J. Tuberc. Lung Dis. 7, 6-21
39. Cho, S. H., Warit, S., Wan, B., Hwang, C. H., Pauli, G. F., and Franzblau, S. G. (2007) Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis Antimicrob. Agents Chemother. 51, 1380-1385 10.1128/AAC.00055-06
40. Hu, Y., Coates, A. R., and Mitchison, D. A. (2006) Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis Int. J. Tuberc. Lung Dis. 10, 317-322
41. Peterson, N. D., Rosen, B. C., Dillon, N. A., and Baughn, A. D. (2015) Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis Antimicrob. Agents Chemother. 59, 7320-7326 10.1128/AAC.00967-15
42. Lee, R. E., Hurdle, J. G., Liu, J., Bruhn, D. F., Matt, T., Scherman, M. S., Vaddady, P. K., Zheng, Z., Qi, J., Akbergenov, R., Das, S., Madhura, D. B., Rathi, C., Trivedi, A., Villellas, C., Lee, R. B., Rakesh, Waidyarachchi, S. L., Sun, D., McNeil, M. R., Ainsa, J. A., Boshoff, H. I., Gonzalez-Juarrero, M., Meibohm, B., Bottger, E. C., and Lenaerts, A. J. (2014) Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux Nat. Med. 20, 152-158 10.1038/nm.3458
43. Lenaerts, A. J., Gruppo, V., Marietta, K. S., Johnson, C. M., Driscoll, D. K., Tompkins, N. M., Rose, J. D., Reynolds, R. C., and Orme, I. M. (2005) Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models Antimicrob. Agents Chemother. 49, 2294-2301 10.1128/AAC.49.6.2294-2301.2005
44. Kelly, B. P., Furney, S. K., Jessen, M. T., and Orme, I. M. (1996) Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis Antimicrob. Agents Chemother. 40, 2809-2812
45. Ryan, G. J., Shapiro, H. M., and Lenaerts, A. J. (2014) Improving acid-fast fluorescent staining for the detection of mycobacteria using a new nucleic acid staining approach Tuberculosis (Oxford, U. K.) 94, 511-518 10.1016/j.tube.2014.07.004
46. Gabrielsson, J. and Weiner, D. (2007) Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 4 th ed., Swedish Pharmaceutical Press, Stockholm, Sweden.
47. Bernillon, P. and Bois, F. Y. (2000) Statistical issues in toxicokinetic modeling: a bayesian perspective Environ. Health Perspect 108 (Suppl. 5) 883-893 10.2307/3454322
48. R. Core Team (2014) R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Ed.) Vienna, Austria.
49. Bois, F. Y. (2009) GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models Bioinformatics 25, 1453-1454 10.1093/bioinformatics/btp162